Amie R. Throneberry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amie R. Throneberry has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrea S. Franks
Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center College of Pharmacy, 1924 Alcoa Hwy, Box 117, Knoxville, TN 37920, USA
1 shared publication Bradley G. Burk
Department of Pharmacy, University of Alabama at Birmingham Medical Center, Birmingham, AL, United States
1 shared publicationBrandon S. Pruett
Department of Psychiatry and Behavioral Neurobiology, University of Alabama Max Heersink School of Medicine, Birmingham, AL, United States
1 shared publicationCarmen C. Coleman
Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center College of Pharmacy, 881 Madison Avenue, Memphis, TN 38163, USA
1 shared publication- Catherine M. Crill
Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center College of Pharmacy, 881 Madison Avenue, Memphis, TN 38163, USA
1 shared publication - Christa M. George
Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center College of Pharmacy, 881 Madison Avenue, Memphis, TN 38163, USA
1 shared publication
Latest Publications
- 27 March 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (7) , 102646
Silos to synergy: Developing collaborative scholarship theme teams for pharmacy faculty
- 27 March 2026
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 18 (7) , 102646
Silos to synergy: Developing collaborative scholarship theme teams for pharmacy faculty
- Open Access
- 1 September 2025
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1659290
Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices
Background: Long-acting injectable antipsychotics (LAI-APs) are vital for managing psychiatric conditions, particularly in patients with adherence challenges. However, errors in medication reconciliation, prescribing, preparation, and administration, often stemming from documentation lapses and communication breakdowns, may result in an increased risk of relapse or readmission. Despite their widespread use, standardized documentation practices remain underdeveloped.Objective: To identify documentation insufficiencies related to LAI-AP use across healthcare settings and propose best practice recommendations to improve safety and care continuity.Methods: A comprehensive review of literature using PubMed, Google Scholar, current clinical guidelines, and gray literature was conducted to identify safety concerns and documentation gaps related to LAI-APs. Search terms included “LAI antipsychotic medication errors,” “documentation,” “safety,” “mental health,” and “medication reconciliation.” Further articles were identified through a scan of the references cited within the initial sources. From this analysis, a series of best practice recommendations were developed targeting key aspects of LAI-AP use, with a focus on practical implementation strategies.Results: Limited literature is available on errors related to LAI-AP with minimal detail on documentation strategies to address these. By reviewing reports, extrapolating recommendations from their oral antipsychotic counterparts, and analyzing potential risk factors unique to the behavioral health setting, key documentation gaps were identified across the LAI-AP use process. These include deficiencies in medication reconciliation—especially related to last doses and oral overlap—along with inconsistencies in prescribing practices, patient education, preparation, administration, and transitions of care. Inadequate documentation contributes to missed or duplicate doses, incorrect administration techniques, and poor coordination between settings. Our findings indicate the need for standardized order sets, readily accessible documentation of initiation or discontinuation reasoning, integration of therapeutic drug monitoring and symptom tracking tools, structured patient education, and formalized transitions of care procedures.Conclusions: Enhancing documentation throughout the LAI-AP care continuum is crucial to reduce medication errors and improve patient outcomes. The proposed framework offers practical steps for clinicians and health systems to standardize documentation, improve communication during care transitions, and promote safer LAI-AP use. Innovations such as national electronic health records, EHR-integrated LAI-AP registries, and smartphone apps could facilitate cross-setting communication, patient engagement, and error reduction. Addressing systemic barriers will require policy-level reform.
- 1 September 2025
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1659290
Open AccessOptimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices
Background: Long-acting injectable antipsychotics (LAI-APs) are vital for managing psychiatric conditions, particularly in patients with adherence challenges. However, errors in medication reconciliation, prescribing, preparation, and administration, often stemming from documentation lapses and communication breakdowns, may result in an increased risk of relapse or readmission. Despite their widespread use, standardized documentation practices remain underdeveloped.Objective: To identify documentation insufficiencies related to LAI-AP use across healthcare settings and propose best practice recommendations to improve safety and care continuity.Methods: A comprehensive review of literature using PubMed, Google Scholar, current clinical guidelines, and gray literature was conducted to identify safety concerns and documentation gaps related to LAI-APs. Search terms included “LAI antipsychotic medication errors,” “documentation,” “safety,” “mental health,” and “medication reconciliation.” Further articles were identified through a scan of the references cited within the initial sources. From this analysis, a series of best practice recommendations were developed targeting key aspects of LAI-AP use, with a focus on practical implementation strategies.Results: Limited literature is available on errors related to LAI-AP with minimal detail on documentation strategies to address these. By reviewing reports, extrapolating recommendations from their oral antipsychotic counterparts, and analyzing potential risk factors unique to the behavioral health setting, key documentation gaps were identified across the LAI-AP use process. These include deficiencies in medication reconciliation—especially related to last doses and oral overlap—along with inconsistencies in prescribing practices, patient education, preparation, administration, and transitions of care. Inadequate documentation contributes to missed or duplicate doses, incorrect administration techniques, and poor coordination between settings. Our findings indicate the need for standardized order sets, readily accessible documentation of initiation or discontinuation reasoning, integration of therapeutic drug monitoring and symptom tracking tools, structured patient education, and formalized transitions of care procedures.Conclusions: Enhancing documentation throughout the LAI-AP care continuum is crucial to reduce medication errors and improve patient outcomes. The proposed framework offers practical steps for clinicians and health systems to standardize documentation, improve communication during care transitions, and promote safer LAI-AP use. Innovations such as national electronic health records, EHR-integrated LAI-AP registries, and smartphone apps could facilitate cross-setting communication, patient engagement, and error reduction. Addressing systemic barriers will require policy-level reform.